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Abstract
Purpose of the Review This review summarizes advances in
treatments for adults with borderline personality disorder
(BPD) in the last 5 years.
Recent Findings Evidence-based advances in the treat-
ment of BPD include a delineation of generalist models
of care in contrast to specialist treatments, identification
of essential effective elements of dialectical behavioral
therapy (DBT), and the adaptation of DBT treatment to
manage post-traumatic stress disorder (PTSD) and BPD.
Studies on pharmacological interventions remain limited
and have not provided evidence that any specific medi-
cations can provide stand-alone treatment.
Summary The research on treatment in BPD is leading to
a distillation of intensive packages of treatment to be
more broadly and practically implemented in most treat-
ment environments through generalist care models and
pared down forms of intensive treatments (e.g., informed
case management plus DBT skills training groups).
Evidence-based integrations of DBT and exposure therapy
for PTSD provide support for changing practices to simul-
taneously treat PTSD and BPD.
Keywords Borderline personality disorder . Psychotherapy .
General psychiatric management . Dialectical behavior
therapy .Mentalization-based treatment .
Transference-focused psychotherapy . Schema-focused
therapy
Introduction
Once thought to be an untreatable condition, borderline per-
sonality disorder (BPD) is now effectively treated by a grow-
ing number of evidence based psychotherapeutic treatments.
Twenty-five years ago, Marsha Linehan published the first
randomized control trial (RCT) for dialectical behavioral ther-
apy (DBT), which yielded more significant reduction in the
disorder’s most challenging features—parasuicidal behavior,
inpatient psychiatric stays, and treatment drop out—than treat-
ment as usual (TAU). Since then, over 13 manualized psycho-
therapies for BPD have been tested. Five major treatments—
DBT, mentalization-based treatment (MBT) [1], schema-
focused therapy (SFT) [2], transference-focused psychothera-
py (TFP) [3], and systems training for emotional predictability
and problem solving (STEPPS) [4]—have been established as
evidence based treatments (EBTs) for BPD [5]. In contrast,
trials testing psychopharmacologic treatments have not
yielded consistent results [6, 7]; therefore, to date no medica-
tion has an official indication for BPD [8•]. This review will
summarize major findings of what works in treatments for
BPD, with a special emphasis on developments in the last
5 years.
The Cochrane review of psychological therapies for bor-
derline personality disorder, which analyzed 28 studies pub-
lished until 2011, is among the most significant additions to
the literature on treatments for BPD in the last 5 years [5]. The
major randomized controlled studies can be characterized in
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four major waves (Table 1). The first wave of studies com-
pared specialized therapies for BPD to TAU. In this first wave
of studies, DBTandMBTwere established as EBTs [1, 9–11].
Additionally, a short-term group therapy, STEPPS, was added
to TAU and found to be more effective than TAU alone in
reducing symptoms of BPD, negative mood states, and impul-
sivity while increasing functioning [4].
Responding to criticisms that treatments lead by experts
had an obvious advantage to TAU, investigators in subsequent
trials in the second wave compared specialized BPD treat-
ments, such as DBTand TFP, to treatment by expert therapists
in the community, known for their willingness and interest in
patients with BPD [21, 22]. DBT again showed higher reduc-
tion in suicidal behavior and self-injury, inpatient hospitaliza-
tion, and treatment drop out than treatment by other experts in
the community [21]. Similarly, in the trial comparing TFP to
treatment by community experts, TFP yielded greater im-
provements in not only suicide attempts, inpatient hospitali-
zation, and treatment drop out, but also in borderline symp-
toms, psychosocial functioning, and personality functioning
[22]. Treatment by experts was as effective as specialty treat-
ments in reducing depressive symptoms, and in the DBT trial,
treatment by experts was effective in reducing suicidality, but
not to the degree achieved in DBT [21, 22].
The third wave of studies staged head-to-head trials be-
tween specialist treatments (i.e., TFP vs. DBT [3]; SFT vs.
TFP [2]). The evidence suggested a variety of systematic
and well-informed manualized psychotherapies were effective
at treating BPD and little was to be gained at horseracing to
determine the superiority of any of them [27]. Clarkin’s TFP
trial straddles both the third and fourth wave of studies [3]. It
incorporated a systematic, manualized supportive therapy as a
third comparison treatment to TFP and DBT. All three treat-
ments, which were systematic and supervised, yielded im-
provements in depression, anxiety, and functioning [3].
While the supportive therapy arm failed to match reductions
in suicidality yielded by both DBT and TFP, it proved effec-
tive enough to be an alternative to treating BPD patients in the
absence of DBT and TFP treatments.
The other fourth wave of studies compared specialist ther-
apies to systematic and well-informed generalist approaches
to managing BPD. These studies aimed to show that the core
ingredients to the specialist treatments provided increased
gains in treatment, apart from the well organized and well-
informed aspects of the clinical approach [3]. Unexpectedly,
these enhanced, structured, and well-informed generalist treat-
ment approaches performed as well in most ways to their
already established specialized counterparts. Structured clini-
cal management (SCM) [25, 28] and general psychiatric man-
agement (GPM) [8•, 24] emerged to provide less specialized
means of managing BPD in the general patient population.
Additionally, supportive therapy, when delivered in a system-
atic way [3] or by experienced clinicians in a group format
[26], proved comparable in outcomes to TFP andMBT.When
clinicians treating a general caseload of patients cannot often
commit the time and expense to training for the gold standard
specialist treatments for BPD [29], SCM, GPM, and support-
ive therapy offer practical, less intensive, “good enough” treat-
ment options.
While generalist approaches to BPD could widen access to
evidence-based care, research dismantling differing aspects of
effective, but complex and intensive treatments, can clarify
their essential elements. Linehan and colleagues published a
dismantling study of DBT, illustrating that a simplified ver-
sion of DBT, involving skills training group combined with
weekly case management was effective in treating problems
of self-harm, suicidality, and use of hospitalization [30•].
Generalist care, with the addition of targeted short-term ad-
junctive interventions in group formats or aimed at suicidality
[4, 18, 31] may complement supportive or generalist ap-
proaches to yield good outcomes, with the investment of few-
er clinical resources.
Investigators have also adapted the established evidence
based treatments for BPD to manage the usual complex co-
morbidities of BPD including substance use disorders
Table 1 Major waves of RCTs for BPD treatment
Wave 1: vs. TAU
DBT Linehan et al. [11] 1991
DBT Linehan et al. [10] 1994
DBT Koons et al. [9] 2001
DBT Carter et al. [12] 2010
DBT Priebe et al. [13] 2012
DBT PTSD Steil et al. [14] 2010
DBT PTSD Bohus et al. [15•] 2013
MBT Bateman & Fonagy [1] 1999
MBT-A Rossouw & Fonagy [16] 2012
CBT+TAU Davidson et al. [17] 2006
MACT Weinberg et al. [18] 2006
STEPPS + TAU Blum et al. [4] 2008
STEPPS + adjunctive therapy Bos et al. [19] 2010
DDP Gregory et al. [20] 2008
Wave 2: vs. community experts
DBT Linehan et al. [21] 2006
TFP Doering et al. [22] 2010
Wave 3: vs manualized treatment
SFT vs TFP Giesen-Bloo et al. [2] 2006
DBT vs DDP vs TAU Sachdeva et al. [23] 2013
TFP vs DBT vs supportive therapy Clarkin et al. [3] 2007
Wave 4: vs. generalized treatment
DBT vs GPM McMain et al. [24] 2009
MBT vs SCM Bateman & Fonagy [25] 2009
MBT vs supportive group therapy Jørgensen et al. [26] 2013
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substance use disorders (SUDs) [32], eating disorders (EDs)
[33], and post-traumatic stress disorder (PTSD) [34]. BPD
patients who present with acutely symptomatic co-
morbidities of these types are often challenging to manage
with strictly BPD oriented treatments [35]. Conversely, in
SUD and ED treatments, individuals with co-morbid BPD
may also present with problems that are difficult to manage
in those treatment environments. Efforts to target BPDwith its
co-morbid disorders simultaneously have been developed and
studies of their feasibility and effectiveness have been pub-
lished in the last 5 years [15•, 32, 33, 36, 37, 38].
The remainder of this review will describe the prevailing
evidence-based psychotherapies for BPD, the newer general-
ist management approaches for BPD, dismantling studies of
evidence-based treatments (EBTs) for BPD, adaptations of
EBTs for complex co-morbidities, and the current state of
knowledge on psychopharmacologic interventions for BPD.
This overview will demonstrate trends to paring down treat-
ments to what essentially works for BPD, that most clinical
settings can consider implementing as a more clear and feasi-
ble standard of care.
Specialized Evidence-Based Treatments (EBTs) for BPD
Dialectical Behavioral Therapy (DBT)
The most well-known, well researched, and widely available
EBT for BPD is DBT [39, 40]. Informed by clinical experi-
ence with suicidal personality disordered patients who did not
improve with standard cognitive behavioral therapy interven-
tion, Linehan developed DBT by incorporating the concept of
dialectics and the strategy of validation into a treatment fo-
cused on skills acquisition and behavioral shaping. DBT for-
mulates the problems of BPD as a result of the transaction
between individuals born with high emotional sensitivity
and “invalidating environments” that is, people or systems
(i.e., families, schools, treatment settings, workplaces) that
cannot perceive, understand, and respond effectively to their
vulnerabilities.
DBT proposes that individuals with BPD can becomemore
effective in managing their sensitivities and interactions with
others through acquisition of skills that enhance mindfulness
and enable them to better tolerate distress, regulate their emo-
tions, and manage relationships. The full empirically validated
package of DBT includes 1 h of weekly individual therapy, a
2-h group skills training session, out-of-session paging, and
consultation team for the therapist. The intensity and structure
of DBT, which is organized in an explicit, comprehensive set
of manuals with instruction to therapists as well as hundreds of
skills worksheets, provides an instant foundation for practi-
tioners of any discipline or level of experience. DBT is de-
signed for teams of clinicians and is among the most time
intensive modalities for patients and clinicians. Its major
mechanism of change occurs via acquisition and generaliza-
tion of skills to be more emotionally regulated, mindful, and
effective in the face of individual sensitivities.
Mentalization-Based Treatment (MBT)
Mentalization refers to the complex capacity human beings
develop to imagine the thoughts and feelings in one’s own
and other’s minds to understand interpersonal interactions
[41]. Therein lies its mechanism of change. MBT proposes
that BPD symptoms arise when a patient stops mentalizing,
leading patients to operate from pathologically certainty about
other’s motives, the disconnection from grounding influence
of reality, and a desperate need for proof of feelings through
action. Attachment interactions become hyperactivated, feed-
ing into distress and difficulty coping, rather than providing
safety and security, rendering the therapeutic process with
BPD difficult.
MBT aims to stabilize the problems of BPD by strengthen-
ing the patient’s capacity to mentalize under the stress of at-
tachment activation [41]. MBT therapists adopt a stance of
curiosity, and “not knowing” in order to encourage patients
to assess their emotional and interpersonal situation through a
more grounded, flexible, and benevolent lens. Prioritizing the
maintenance of mentalizing, MBT therapists support patients
to think through hyperactivated states themselves, rather than
providing prepackaged or intellectualized explanations, in-
sights, or skills. Outpatient MBT involves 50 min of weekly
individual therapy, 75 min of group therapy, and a reflecting
team meeting which serves to support clinical team members
in their mentalization in the process of treatment [25].
Developed within the National Health Services (NHS) in the
United Kingdom, MBT provides a tenable model for treating
personality disordered patients settings where patients and cli-
nicians face scarce resources.
Transference-Focused Psychotherapy (TFP)
Based on the conceptualization of borderline personality
organization introduced by Otto Kernberg in the 1960s,
transference-focused psychotherapy (TFP) is a manualized,
psychoanalytically oriented psychotherapy. Kernberg defined
identity diffusion, primitive defense mechanisms (e.g., split-
ting), unstable reality testing, internally and externally
expressed aggression, and conflicted internal working models
of relationships as key features of personality disorders at
borderline level of organization [42].
TFP’s focus is the problematic interpersonal dynamics in
the patient’s life and their resultant intense emotional states.
The patient’s inherent interpersonal dynamic emerge in inter-
actions with the therapist in the transference, and are jointly
examined to resolve the splits between good and bad that drive
instabilities in affect and relationships. Like MBT, TFP’s
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mechanism of change occurs through helping patients achieve
more balanced, integrated, and coherent ways of thinking
about oneself and others. TFP involves two weekly individual
therapy sessions, without group therapy. Clinicians in TFP are
encouraged to receive supervision. TFP is more compatible
with treatments by individual clinicians, not working in teams.
Schema-Focused Therapy (SFT)
Schema-focused therapy (SFT) is an integrative cognitive
therapy focused on generating structural changes to a patient’s
personality. In twice weekly individual therapy sessions, the
clinician uses a variety of behavioral, cognitive, and experien-
tial techniques that focus on the therapeutic relationship, daily
life outside therapy, and past traumatic experiences. Unlike
the more neutral stances of other therapies, SFT encourages
an attachment between therapist and client, a process de-
scribed as “limited re-parenting”. Therapy focuses on four
schema modes of BPD: detached protector, punitive parent,
abandoned/abused child, and angry/impulsive child. Its mech-
anism of change occurs through changing negative patterns of
thinking, feeling, and behaving and developing healthier al-
ternatives to replace them so that these dysfunctional schemas
no longer control a patient’s life.
Generalist Approaches to BPD
General Psychiatric Management (GPM)
Given the limitations of treatment models that require signif-
icant training and significant clinic resources, there is a need to
develop, test, and disseminate less intensive treatments. One
of these new EBTs is general psychiatric management (GPM)
[8•].
GPM is based on a case management model, where inter-
ventions rely on common sense and are learned easily by
generalist clinicians. Inherent in the case management ap-
proach is a focus on the patient’s life outside of therapy.
GPM prioritizes the attainment of stable vocational function-
ing over romantic relationships, as well as improvement in
social functioning over specific symptom improvement.
Diagnostic disclosure with a discussion of the disorder’s
symptoms should be the first step in psychoeducation for pa-
tients and their families, followed by information about the
disorder’s etiology and positive prognosis. This frames a dis-
cussion of treatment frequency and duration—treatment is
only provided if it is helping the patient progress based on
articulated goals. GPM rarely involves more than one weekly
individual appointment. The treatment is multimodal in nature
and provides guidance for psychopharmacological interven-
tions, as well as the provision of group and family therapy and
coordination across providers. Its mechanism of change is to
facilitate the natural course of the disorder’s improvement
with specific attention to promoting functioning in endeavors
outside of treatment.
What may be most specific to GPM is its central focus on
an interpersonal hypersensitivity model of BPD [43]. In this
model, the symptoms of BPD are understood as resulting from
an emotional cascade that begins with an interpersonal stress-
or (e.g., separation, criticism). The therapist actively hypoth-
esizes that any emotion dysregulation, impulsive or self-
harming behavior, or hospitalization has resulted from an in-
terpersonal problem, and works with the patient to better un-
derstand his or her sensitivities and responses.
In a randomized trial of GPM versus DBT, McMain et al.
[24] found that patients in both treatments showed significant
and comparable improvement across a variety of clinical out-
comes measures after 1 year. Results were consistent at 2-year
follow-up [44]. Furthermore, this trial later demonstrated that
of patients with high Axis 1 co-morbidity, those assigned to
GPM had significantly lower dropout rates than their DBT
counterparts [45]. Moreover, there is evidence that attending
a 1-day GPM workshop improves clinicians’ attitudes about
treating BPD. For example, clinicians report feeling more
hopeful, competent, and open to treat BPD [46]. These find-
ings are particularly important given that BPD is a disorder for
which significant stigma may introduce barriers to successful
treatment. The success of treatment dissemination depends in
large part on whether clinicians are willing to use treatments
and feel competent to do so.
Structured Clinical Management (SCM)
Structured clinical management (SCM) was developed in the
UK, similar to GPM, reflects “best general psychiatric treat-
ment” that is feasible for use by “generalist mental health
clinicians” with minimal additional training [47, p. 57]. It
was developed based on “expert consensus” about what gen-
eral practices work best for treating BPD, and has been tested
primarily in the context of RCTs evaluating the effectiveness
of MBT [25]. Compared to patients who receivedMBT, those
who received SCM showed substantial improvements across
an array of clinical outcomes. Patients receiving MBT im-
proved somewhat more quickly and continued to show greater
benefit than SCM at 18-month follow-ups. However, those
who received SCM were as well at 6 months as those in the
MBT group, and showed faster reductions in self-harm.
Like GPM, SCM provides a structured framework for
approaching treatment for BPD (see Table 2 for compari-
sons). This framework is guided by a number of generalist
principles and is meant to make treatment understandable
and predictable for patients. There is an emphasis on sharing
the borderline diagnosis with patients, psychoeducation, al-
liance building that is based both on contractual (e.g., goal
agreement) and relational factors (e.g., trust, reliability, lik-
ing), encouragement of family involvement, limited reliance
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on psychopharmacological intervention, some guidance on
managing co-morbid conditions, and explicit safety plan-
ning. Both GPM and SCM recommend intersession contact
be used sparingly. However, SCM takes a more cautious
approach, advocating for “vigorously supporting the patient
on the telephone if necessary” [47, p. 69], vehemently pur-
suing clients who have not come to treatment, and a will-
ingness to meet them at home or elsewhere when safety risk
is elevated. This may have more to do with differences in
the legal climate of the UK versus the USA than with beliefs
about the utility of intersession contact. Also, SCM includes
specifically articulated weekly group therapy. Group therapy
is open on a rolling basis for patients and includes
psychoeducation and a framework focused on problem
solving.
SCM has considerable similarity to GPM in terms of
training requirements, structure, and general principles.
However, descriptions of therapeutic techniques employed
in SCM suggest that in some respects, it may appear more
similar to MBT than GPM in practice. GPM is less psy-
chotherapeutically oriented than other evidence-based
treatments for BPD [29]. The general therapeutic stance
includes responsivity, appropriate self-disclosure, flexibil-
ity, and pragmatism. The nonspecific techniques and ther-
apeutic stance employed in SCM are generally rooted in
psychodynamic principles consistent with MBT. These
include authenticity and openness, the adoption of a “not
knowing” stance, a focus on misunderstandings in the re-
lationship, and generation of curiosity about belief and
intentions.
Dismantling Studies
Now that several evidence-based treatments for BPD have
been tested, their most essential ingredients can be discerned
from dismantling studies. A major advance in the last 5 years
for understanding what works in BPD treatment comes from
Linehan’s dismantling study of DBT. DBT in its standard
form involves an intensive package of weekly individual ther-
apy, weekly two and a half hour skills training group, 1-h
consultation team for the therapist, and paging for skills
coaching available between sessions. Linehan and colleagues
compared this full, or “standard DBT” package to DBT indi-
vidual therapy (DBT-I) without DBT skills training group as
well as DBT skills training group (DBT-S) without skills
coaching [30•]. All packages of DBT demonstrated significant
improvements in suicidality and reduction in use of crisis ser-
vices. While standard DBT showed greater improvement in
frequency of self-harm, anxiety, and depression than the DBT-
I condition, it did not show significant gains over DBT-S
despite the significant difference in total hours of treatment
(average 55.3 h in standard DBT versus 31.7 h in DBT-S).
Table 2 Comparison of GPM
and SCM GPM [8] SCM [47]


















Individual therapy • 1/week PRN if working • 1/week
Group therapy • Encouraged • Required problem-solving group 1.5 h/wk
Family involvement • Psychoeducation
• Multi-family groups
• 2-session intervention
• Further sessions PRN
Intersession contact • Use sparingly • Use sparingly
• Case management PRN




Co-morbidities • Specific hierarchies (e.g., BPD
considered primary to MDD)
• BPD primary to MDD
• Substance use/dependence managed with
adjunctive care
Medications • Conservative approach • Conservative approach
• Prescribe for co-morbid conditions not BPD
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Linehan’s component analysis advances an imperative to dis-
till the specialized and resource intensive EBTs for BPD to its
most basic effective parts for the broadest, most resource ef-
ficient implementation.
Other Brief Cost-Effective Options
Systems Training for Emotional Predictability and Problem
Solving (STEPPS)
Designed to supplement ongoing treatments such as medica-
tion, individual therapy, and case management, systems train-
ing for emotional predictability and problem solving
(STEPPS) consists of cognitive behavioral elements, skills
training, and a systems component. The STEPPS program
includes 20 weeks of 2-h seminar-like group sessions. Two
co-facilitators lead the sessions by following detailed lesson
plans that cover three main components of STEPPS. The first
component, psychoeducation, focuses on reframing BPD as
an “emotional intensity disorder,” correcting misconceptions
about BPD, and helping participants gain an awareness of the
schemas that drive their behaviors. The second, emotion man-
agement skills trainings, teaches skills to better manage the
effects of BPD including distancing, communicating, and
problem management. The third, behavior management skills
training, covers goal setting, healthy eating, sleep, and exer-
cise habits, self-harm avoidance, and interpersonal effective-
ness. Participants are responsible for course materials and
homework. The skills-based group sessions are supplemented
by a single 2-h psychoeducation and skills training session for
families which accounts for the systems component of
STEPPS. While STEPPS is not designed to be a stand-alone
treatment, a limited body of research indicates that STEPPS’
manualized, supplemental group sessions may enhance con-
current BPD treatments.
More recently, a series of studies conducted by Black and
colleagues [48] explored the effectiveness of STEPPS for
BPD patients with co-morbid antisocial personality disorder
(ASPD) in both university and correctional settings. The find-
ings indicate that subjects with co-morbid ASPD experienced
similar or greater improvement in BPD symptoms, impulsive-
ness, and global symptoms than their non-ASPD counterparts
and that STEPPS treatment is effective. These preliminary
findings suggest that STEPPS has potential for treating a
uniquely difficult to treat population: offenders with co-
morbid BPD and ASPD.
Treatments for BPD and Major Co-morbidities
BPD’s usual complex pattern of co-morbidity [49, 50] is an-
other challenging factor in its clinical management. While
depression is its most common co-morbidity, co-occurring
with BPD in the majority of cases [50], evidence from RCTs
presented here suggest it responds to specialist and generalist
approaches, and tends to improve when BPD improves [51].
Other common co-morbidities such as substance use disorders
(SUDS) [32], eating disorders (EDs) [33], and post-traumatic
stress disorder (PTSD) [34] have been shown to lead to poorer
treatment outcomes in some trials. While some evidence ex-
ists that these co-occurring disorders respond to DBT [35],
MBT [52], and GPM [53], the combination of self-harm or
suicidality with active substance dependence or eating disor-
der often makes these patients ineligible for specific treatment
programs in clinical practice. The application and adaptation
of some of the EBTs reviewed here have begun to elucidate
direction in the simultaneous management of these challeng-
ing co-morbidities.
Substance Use Disorders (SUDs)
Two reviews of interventions for co-occurring BPD and SUDs
were published in the last 5 years [32, 38]. These reviews
indicate that DBT, in standard form as well as adapted in
combination with opiate agonist medication, resulted in great-
er improvement of SUD, than either opiate agonist medication
alone or treatment by community experts [35, 54]. In addition,
dynamic deconstructive psychotherapy (DDP) [55], a
manualized psychodynamic treatment for BPD and alcohol
use disorders aimed at integrating and verbalizing emotional
experiences as well as enhancing interpersonal identity and
interactions through greater differentiation of self and other,
showed greater improvements in BPD and alcohol use prob-
lems than TAU [20].
Eating Disorders
A limited number of studies have suggested that some indi-
viduals with co-morbid EDs and BPDwill respond to standard
DBT treatment [35, 56]. One study adapted DBT for EDs in a
3-month inpatient treatment, with improvement in both bulim-
ia nervosa (BN) and anorexia nervosa (AN), resulting in re-
mission rates higher than reported for standard DBT from
other studies [33]. The impact of this modified form of DBT
was more robust for BN than AN. MBT has been adapted to
treat the combination of BPD and ED [37], but results of this
trial are yet to be published.
Post-Traumatic Stress Disorder (PTSD)
Of the three complicating co-morbidities for BPD presented
here, the clearest progress in treatment in the last 5 years has
developed for treatment of BPD and PTSD. While BPD pa-
tients commonly have co-occurring PTSD (approximately
30% in community samples and 50% in clinical samples)
[36], guidelines for treating both simultaneously did not exist
until recently. Common practice prior to these studies
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assumed BPDwould need attention first, and then PTSDwork
would follow. Standard PTSD protocols have been contrain-
dicated in the context of active self-harm or suicidality [57].
Two different DBT research groups have published positive
trials on adaptations of DBT for co-morbid PTSD, one adding
exposure protocols to standard DBT [15•, 36] and the other
modifying standard DBT to address severe PTSD symptoms at
the outset of treatment [28]. The first of these trials [15•] fo-
cused on PTSD associated with the most complex and severe
forms of trauma, for example childhood sexual abuse, in a 3-
month residentially based treatment, reporting significant re-
ductions in PTSD-related symptoms when compared to TAU
(waitlist). This distilled adaptation to DBT focuses on exposure
with anti-dissociation skills, emotional regulation regarding
shame and guilt, and acceptance on the trauma and the feelings
a patient has surrounding it. The second trial [36] compared
standardDBT toDBT plus a DBT prolonged exposure protocol
(DBT-PE), conducted in an outpatient setting over 12 months.
This second smaller study demonstrated the superiority in the
enhanced DBT-PE treatment in terms of reduction of PTSD-
related symptom as well as suicidality and self-injury. These
two trials suggest co-morbid PTSD and BPD can be concur-
rently treated with DBT and exposure protocols effectively.
Bohus’s trial was a larger study involving 29 patients in a nat-
uralistic treatment setting and a waitlist comparison group of 29
patients. It employed a pared down and concentrated version of
DBT without a need to prioritize attention to self-harming be-
haviors, or to wait for a reduction in suicidality or self-harm to
start the treatment. Harned’s trial was small, with ten of 17
DBT-PE patients completing the treatment, compared to five
of nine completing standard DBTas its comparison group. The
results of these trials suggest changing notions that these two
disorders cannot be treated concurrently, or that significant sta-
bilization need to occur prior to initiating PTSD focused work.
Further research is needed to replicate these results.
Pharmacology
Compared with the growing evidence base for effective psy-
chological treatments, pharmacologic treatments for BPD re-
main less well-studied. To date, no medication has been ap-
proved by the FDA for BPD or proven to definitively manage
its cardinal symptoms, interpersonal impairments, and func-
tional difficulties. Clinical applicability of the available evi-
dence is hampered by a limited number of studies, small sam-
ple sizes, non-overlapping batteries of outcome measures,
brief observation periods, and exclusion of co-morbidities in
a population for whom both psychiatric and medical co-
morbidity are the rule rather than an exception.
Studies of prescribing practices indicate little conformity
with the existing humble evidence-base. BPD patients are com-
monly subject to psychotropic polypharmacy, more likely to
receive all classes of psychotropics, except TCAs and MAOIs
[58]. After 16 years of prospective follow-up, 18.6 and 6.9% of
BPD patients report taking four or more and five or more psy-
chotropic medications, respectively [59]. In the same cohort
over 14 years of follow-up, nearly one-third consistently used
PRN medication despite the absence of any evidence-based
protocols for prescribing PRNs for BPD [60]. The wish to be
helpful and perceived “pressure to do something” for patients
presenting in acute distress reporting unrelenting agitation, anx-
iety, and insomnia may account for the tendency to prescribe
outside of evidence-based parameters.
In an attempt to offer sensible clinical roadmaps, practice
guidelines have been proposed by regulatory organizations and
thought leaders. The American Psychiatric Association (APA)
guidelines proposed a symptom-targeted approach using specific
medication classes to treat specific BPD symptom domains [61].
Their recommendations include the use of SSRIs for symptoms
of affective dysregulation and impulsivity, and low-dose atypical
antipsychotics for “cognitive-perceptual” symptoms such as tran-
sient stress-induced paranoia and dissociation. These guidelines
have been criticized for being based on an artificial construct of
the psychobiology of personality disorders, an overreliance on
reconstructions of retrospective data, and the lack of adequately
powered RCTs to inform their recommendations [62].
In contrast, the UK-based National Institute for Clinical
Excellence (NICE) guidelines revised in 2015 conclude from
its review of available RCTs that the evidence is not robust
enough to inform any prescribing practices, citing the study
limitations discussed above [63]. NICE recommends against
using any medications for BPD or specific associated symp-
toms, but suggests they should be used for true co-morbidities
and hesitantly allows their short-term use during acute crisis.
Subsequent meta-analyses have extended the “symptom
domain” model that informed the APA guidelines to extrapo-
late across variable outcome measurements between individ-
ual studies. The Cochrane review meta-analysis found that
although differences between drugs were not statistically dif-
ferent and effects were modest at best, improvement was seen
in all symptom domains of BPD with psychopharmacological
treatment [7]. Affective dysregulation was found to improve
with haloperidol, aripiprazole, olanzapine, lamotrigine,
divalproex, and topiramate, with no significant differences
between these medications or classes. Behavioral dyscontrol/
impulsivity improved with aripiprazole, topiramate, and
lamotrigine. Cognitive-perceptual symptoms improved with
aripiprazole and olanzapine. Interestingly, no SSRIs were
found to improve any domain of symptoms and no medica-
tions alleviated certain core BPD symptoms, including avoid-
ance of abandonment, chronic feelings of emptiness, identity
disturbance, and dissociation. A second meta-analysis by
Ingenhoven et al. identified a larger effect size for mood sta-
bilizers on the treatment of behavioral dyscontrol-impulsive
behaviors and anger and a more pronounced effect on global
functioning, especially for lamotrigine and topiramate [64].
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Of the psychotherapeutic approaches reviewed here, only
GPM and SCM incorporates specific psychopharmacological
guidelines, which combine elements of NICE and APA guide-
lines [8•]. Principled, yet flexible approaches to prescribing
attempts to strike a balance between the evidence-based per-
spective that medications appear at best adjunctive while also
being potentially harmful and the clinical wisdom that medi-
cation may be cautiously used in a symptom-targeted manner
to promote engagement in psychotherapy. Prescribers are en-
couraged to avoid reactive prescribing and deliver
psychoeducation about suggested medications which includes
appropriate uncertainty about expected benefits.
GPM offers a specific algorithm to help prescribers limit
harm and maximize potential benefit from medications. In this
algorithm, no medications are prescribed for patients who do
not request them and are not in distress. SSRIs are prescribed
for either bona fide co-morbid major depressive episode or for
patients who may have mild distress and request a medication.
For behavioral dyscontrol/impulsivity and anger, either a mood
stabilizer or antipsychotic can be prescribed, but risks must be
discussed. For those with cognitive-perceptual disturbance,
low-dose antipsychotics are recommended. In keeping with
NICE guidelines, GPM promotes discontinuing medications
if ineffective, avoiding polypharmacy, and time-limiting use.
Existing guidelines for pharmacotherapy in BPD do not re-
flect consensus but rather a chorus of distinct voices with a few
overlapping refrains. One shared aim is the minimization of
harms by prioritizing psychotherapy whenever possible,
avoiding polypharmacy, adding medications and tapering those
lacking clear efficacy in a stepwise fashion, promoting patients’
collaboration through psychoeducation and joint monitoring of
risks and benefits, and considering the usefulness of prescribing
in view of effects on the therapeutic relationship. Finally, benzo-
diazepines and benzodiazepine-like substances should be
avoided out of concern for promoting dependence, abuse, and
behavioral disinhibition.
Conclusion
Prior to 2011, a number of highly specialized psychotherapies,
(e.g., DBT, MBT, TFP, and SFT) entered the clinical scene as
effective EBTs for BPD. The proliferation of these intensive
EBTs turned the tide of prevailing notions that BPD was an
untreatable condition. However, while effective treatments be-
came more available, the intensity of EBTs for BPD suggested
that BPD could best be treated by specialists. More recently,
structured generalist management approaches such as GPM
and SCM, have also been proven to work for patients with
BPD. A dismantling study of DBT has offered evidence that a
more pared down version of DBT, with skills training group and
case management is nearly as effective as standard resource in-
tensive packages of DBT.
Now less intensive forms of effective treatment for BPD are
more available, providing hope that the general standard of care
for these complex patients can be improved. Some proposals
for determining which patients should received generalist care
versus specialized care have recommended that patients with
either greater personality dysfunction (i.e., greater numbers of
personality disorder diagnoses) [52] or lack of response to gen-
eralist models of care [29] be allocated to a higher more inten-
sive EBT. In contrast to psychotherapy trials, pharmacology
trials suggest medications are adjunctive at best, and best min-
imized except in the treatment of co-morbidities.
Lastly, the BPD treatment research has paid increasing at-
tention to co-morbidities such as SUDs, EDs, and PTSD.
While evidence is accumulating for treatment studies in this
area, clear advances in adapting DBT to treatment for PTSD
has been made in the last 5 years. Now, exposure protocols for
treating PTSD have been incorporated into DBT to help pa-
tients with both BPD and PTSD symptoms. Further research
on adaptations of treatment for patients with more complex
co-morbidities is still needed.
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